These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 24729718)

  • 81. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
    McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
    Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
    [TBL] [Abstract][Full Text] [Related]  

  • 82. MenHibrix: a new combination meningococcal vaccine for infants and toddlers.
    Hale SF; Camaione L; Lomaestro BM
    Ann Pharmacother; 2014 Mar; 48(3):404-11. PubMed ID: 24353263
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Persistence of bactericidal antibodies following primary and booster MenACWY-TT vaccination of toddlers: A review of clinical studies.
    Webber C; Peyrani P; Balmer P; Serra L
    Vaccine; 2020 Jun; 38(27):4236-4245. PubMed ID: 32389497
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Safety and immunogenicity of a tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine in adolescents and adults.
    Bermal N; Huang LM; Dubey AP; Jain H; Bavdekar A; Lin TY; Bianco V; Baine Y; Miller JM
    Hum Vaccin; 2011 Feb; 7(2):239-47. PubMed ID: 21343698
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.
    Saez-Llorens X; Aguilera Vaca DC; Abarca K; Maho E; Graña MG; Heijnen E; Smolenov I; Dull PM
    Hum Vaccin Immunother; 2015; 11(6):1507-17. PubMed ID: 25969894
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra
    Kim HS; Engel S; Neveu D; Thollot Y; Oster P; Yang K
    Infect Dis Ther; 2021 Mar; 10(1):399-409. PubMed ID: 33439463
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US Adolescents.
    Muse D; Christensen S; Bhuyan P; Absalon J; Eiden JJ; Jones TR; York LJ; Jansen KU; O'Neill RE; Harris SL; Perez JL
    Pediatr Infect Dis J; 2016 Jun; 35(6):673-82. PubMed ID: 26974889
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults.
    Gasparini R; Conversano M; Bona G; Gabutti G; Anemona A; Dull PM; Ceddia F
    Clin Vaccine Immunol; 2010 Apr; 17(4):537-44. PubMed ID: 20164251
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study.
    Chen WH; Neuzil KM; Boyce CR; Pasetti MF; Reymann MK; Martellet L; Hosken N; LaForce FM; Dhere RM; Pisal SS; Chaudhari A; Kulkarni PS; Borrow R; Findlow H; Brown V; McDonough ML; Dally L; Alderson MR
    Lancet Infect Dis; 2018 Oct; 18(10):1088-1096. PubMed ID: 30120069
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents.
    Quiambao BP; Bavdekar A; Dubey AP; Jain H; Kolhe D; Bianco V; Miller JM; Van der Wielen M
    Hum Vaccin Immunother; 2017 Mar; 13(3):636-644. PubMed ID: 28152332
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM.
    Kim HW; Park IH; You S; Yu HT; Oh IS; Sung PS; Shin EC; Kim KH
    Yonsei Med J; 2016 Nov; 57(6):1511-6. PubMed ID: 27593883
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.
    Nolan TM; Nissen MD; Naz A; Shepard J; Bedell L; Hohenboken M; Odrljin T; Dull PM
    Hum Vaccin Immunother; 2014; 10(2):280-9. PubMed ID: 24220326
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.
    Lee HJ; Chung MH; Kim WJ; Hong YJ; Choi KM; Lee J; Oh CE; Welsch JA; Kim KH; Hong KB; Dagnew AF; Bock H; Dull PM; Odrljin T
    Int J Infect Dis; 2014 Nov; 28():204-10. PubMed ID: 25316331
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Cohn AC; MacNeil JR; Clark TA; Ortega-Sanchez IR; Briere EZ; Meissner HC; Baker CJ; Messonnier NE;
    MMWR Recomm Rep; 2013 Mar; 62(RR-2):1-28. PubMed ID: 23515099
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine.
    Tejedor JC; Moro M; Ruiz-Contreras J; Castro J; Gómez-Campderá JA; Navarro ML; Merino JM; Martín-Ancel A; Roca J; García-del-Río M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Boceta R; García-Corbeira P; Jacquet JM; Collard A; Schuerman L;
    Pediatr Infect Dis J; 2006 Aug; 25(8):713-20. PubMed ID: 16874171
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
    Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM
    Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Immunogenicity and safety of concomitant administration of a combined hepatitis A/B vaccine and a quadrivalent meningococcal conjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger EC; Meyer S; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(2):105-14. PubMed ID: 25483566
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Immunogenicity and safety of an investigational quadrivalent meningococcal ACWY tetanus toxoid conjugate vaccine in healthy adolescents and young adults 10 to 25 years of age.
    Baxter R; Baine Y; Ensor K; Bianco V; Friedland LR; Miller JM
    Pediatr Infect Dis J; 2011 Mar; 30(3):e41-8. PubMed ID: 21200360
    [TBL] [Abstract][Full Text] [Related]  

  • 100. [Quadrivalent conjugate vaccines against ACWY meningococcal disease].
    Iovene I; Igidbashian S; Franco E
    Ig Sanita Pubbl; 2021; 79(5):625-638. PubMed ID: 34919537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.